SCHEMBL2331949

SCHEMBL2331949

COCCCNC(=O)C1CCCNC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
REN P00797 1/20 0.53
CYP3A4 P08684 2/20 0.51
LMNA P02545 2/20 0.49
EPHX2 P34913 1/20 0.47
KDM4E B2RXH2 3/20 0.46
ALDH1A1 P00352 2/20 0.46
HPGD P15428 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
GAA P10253 1/20 0.46
USP2 O75604 1/20 0.44
HSD17B10 Q99714 1/20 0.44
SLC6A1 P30531 2/20 0.44
SLC6A11 P48066 1/20 0.44
TSHR P16473 1/20 0.44
SLC6A13 Q9NSD5 1/20 0.44
GNAI3 P08754 1/20 0.43
GNAO1 P09471 1/20 0.43
GNAI1 P63096 1/20 0.43
NAAA Q02083 1/20 0.43
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL40045 0.91 REN (0.49) RENCYP3A4LMNAKDM4EALDH1A1
SCHEMBL40044 0.91 REN (0.49) RENCYP3A4LMNAKDM4EALDH1A1
SCHEMBL2413009 0.87 TSHR (0.55) CYP3A4LMNAKDM4EALDH1A1SMN1; SMN2
Hydrochloric Acid SCHEMBL21640532 0.85 CYP3A4 (0.55) CYP3A4LMNAEPHX2KDM4EALDH1A1
SCHEMBL11395001 0.84 NAAA (0.58) LMNAKDM4ESMN1; SMN2GAASLC6A1
SCHEMBL10030564 0.83 SLC6A1 (0.57) RENLMNAKDM4ESMN1; SMN2HSD17B10
Hydrochloric Acid SCHEMBL21640827 0.82 CYP3A4 (0.53) CYP3A4LMNAEPHX2KDM4EALDH1A1
SCHEMBL2223343 0.82 SLC6A1 (0.49) RENLMNAKDM4ESMN1; SMN2SLC6A1
SCHEMBL2324315 0.82 GNAI3 (0.63) CYP3A4LMNAEPHX2KDM4EALDH1A1
SCHEMBL22652025 0.82 NAAA (0.63) CYP3A4LMNAEPHX2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2352732-A1 2, 5-DIAMINO-SUBSTITUTED PYRIDO Ý4, 3-D¨PYRIMIDINES AS AUTOTAXIN INHIBITORS AGAINST CANCER Merck Patent GmbH (DE) 2011-08-10 EP claimed
US-20110237583-A1 2, 5-DIAMINO-SUBSTITUTED PYRIDO [4, 3-D] PYRIMIDINES AS AUTOTAXIN INHIBITORS AGAINST CANCER MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG 2011-09-29 US disclosed
EP-2352732-A1 2, 5-DIAMINO-SUBSTITUTED PYRIDO Ý4, 3-D¨PYRIMIDINES AS AUTOTAXIN INHIBITORS AGAINST CANCER Merck Patent GmbH (DE) 2011-08-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237583-A1 2, 5-DIAMINO-SUBSTITUTED PYRIDO [4, 3-D] PYRIMIDINES AS AUTOTAXIN INHIBITORS AGAINST CANCER ENPP2, PLA2G4A, PLA2G4B REN 2733/4885CYP3A4 4635/4885LMNA 1028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.